Healthy Skepticism Library item: 14922

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: news

Richwine L.
U.S. lets drugmakers advise doctors on unapproved uses
Reuters 2009 Jan 15
http://www.reuters.com/article/email/idUSTRE50B5GK20090112

Full text:

U.S. health officials finalized guidelines that allow pharmaceutical companies to tell doctors about unapproved uses of their medicines, a practice opposed by critics of industry marketing.

The Food and Drug Administration (FDA) guidelines allow manufacturers such as Pfizer Inc and Merck & Co to distribute copies of medical journal articles that describe unapproved uses. The action could help companies expand the markets for medicines and medical devices.

The move, announced a week before Republican President George W. Bush leaves office, puts in place a policy that drew objections from congressional Democrats and drug-industry critics when it was proposed last year. Opponents say it will allow promotion of uses without adequate testing.

By law, manufacturers are prohibited from marketing their medicines for uses not approved by the FDA. But doctors can prescribe drugs for any use they see fit, a practice known as “off-label” use.

Distribution of medical literature suggesting a drug may have merit for an unapproved use is a marketing area that has been in dispute for years.

The FDA said “public health can be served when health-care professionals receive truthful and non-misleading scientific and medical information on unapproved uses.”

Industry critics say allowing companies to distribute the information promotes untested uses of drugs and may be dangerous. It also could deter manufacturers from conducting additional tests of the new uses and subjecting them to FDA scrutiny for possible approval.

Consumer advocate Sidney Wolfe said the guidelines were only recommendations to companies, rather than a formal regulation, and should be reversed quickly after Democrat Barack Obama becomes president next week.

Off-label use “means there isn’t adequate evidence that the benefits outweigh the risks to have it approved by the FDA,” said Wolfe, director of Public Citizen’s Health Research Group. Companies may use off-label promotion “as a way of avoiding having the drug approved” for wider use, he said.

Giving medicines for unapproved uses is common. A doctor may prescribe an antidepressant, for example, to treat insomnia, or a cancer drug for a type of cancer beyond what is approved.

About one of five prescriptions in the United States was written to treat a condition for which the drug was not approved, according to a 2006 study published in the Archives of Internal Medicine. The researchers said most off-label use occurs without scientific support.

Drugmakers welcomed the new FDA guidelines. Providing the studies to doctors will help “assure that medical professionals receive timely and accurate medical information prior to the lengthy process” of securing FDA approval for wider use, said Ken Johnson, a spokesman for the Pharmaceutical Research and Manufacturers of America.

Off-label use “can save lives, especially in practice areas where there are few effective treatments,” he added.

The FDA said articles circulated by companies should come from peer-reviewed journals that require disclosure of conflicts of interest for researchers. It also encouraged companies to seek FDA approval for unapproved uses.

The guidelines also apply to medical device makers.

The FDA proposed the guidelines in February 2008 and took public comments before finalizing them.